Sort   by:  
 Page size 
UnknownConcomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells.
Not available
S-EPMC3750747 | biostudies-literature
UnknownIbrutinib and Venetoclax for First-Line Treatment of CLL.
Not available
S-EPMC11827445 | biostudies-literature
UnknownClearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.
Not available
S-EPMC6008108 | biostudies-literature
UnknownMethyl 2-cyano-3,12-dioxooleana-1,9-dien-28-oate decreases specificity protein transcription factors and inhibits pancreatic tumor growth: role of microRNA-27a.
Not available
S-EPMC2917860 | biostudies-literature
UnknownSimultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia.
Not available
S-EPMC1895551 | biostudies-literature
UnknownPrognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin.
Not available
S-EPMC4060157 | biostudies-literature
Unknownp53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α-mediated down-regulation of CXCL12.
Not available
S-EPMC3204912 | biostudies-literature
UnknownFinal report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Not available
S-EPMC4420214 | biostudies-literature
UnknownTargeting connective tissue growth factor (CTGF) in acute lymphoblastic leukemia preclinical models: anti-CTGF monoclonal antibody attenuates leukemia growth.
Not available
S-EPMC3948212 | biostudies-literature
UnknownPhase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia.
Not available
S-EPMC11756386 | biostudies-literature
Sort   by:  
 Page size